Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
Nasreen S, Jiang Y, Lu H, Lee A, Cutland CL, Gentile A, Giglio N, Macartney K, Deng L, Liu B, Sonneveld N, Bellamy K, Clothier HJ, Sepulveda Kattan G, Naus M, Naveed Z, Janjua NZ, Nguyen L, Hviid A, Poukka E, Perälä J, Leino T, Chandra LA, Thobari JA, Park BJ, Choi NK, Jeong NY, Madhi SA, Villalobos F, Solórzano M, Bissacco CA, Carreras-Martínez JJ, Correcher-Martínez E, Urchueguía-Fornes A, Roy D, Yeomans A, Aurelius T, Morton K, Di Mauro G, Sturkenboom MC, Sejvar JJ, Top KA, Batty K, Ghebreab L, Griffin JB, Petousis-Harris H, Buttery J, Black S, Kwong JC.
Nasreen S, et al. Among authors: poukka e.
Vaccine. 2025 Jul 11;60:127291. doi: 10.1016/j.vaccine.2025.127291. Epub 2025 May 28.
Vaccine. 2025.
PMID: 40440921
Free article.